fumarates and Cystic-Fibrosis

Methicillin-resistant

Topics: Acetylglucosamine; Adult; Animals; Biofilms; Bronchi; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Cytokines; Female; Fumarates; Gentamicins; Glucose; Humans; Lung Diseases; Malates; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred C57BL; Middle Aged; Phylogeny; Pneumonia, Staphylococcal; Pyruvic Acid; Staphylococcal Infections; Transcription, Genetic; Tricarboxylic Acids; Whole Genome Sequencing

Bacterial persisters are a quasidormant subpopulation of cells that are tolerant to antibiotic treatment. The combination of the aminoglycoside tobramycin with fumarate as an antibacterial potentiator utilizes an antipersister strategy that is aimed at reducing recurrent

Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Fumarates; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin

Three secondary metabolites of lichens - usnic acid, atranorin and fumarprotocetraric acid - were evaluated for their in vitro antibacterial and antibiofilm activities against three strains each of methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MRSA) from cystic fibrosis patients.. Antibacterial activity was assessed by broth microdilution, while antibiofilm activity was evaluated by spectrophotometry or viable count.. Usnic acid was significantly more active than atranorin against planktonic cells, while fumarprotocetraric acid exhibited no activity. Atranorin was the most effective in counteracting adhesion to polystyrene, although usnic acid was more active against MRSA. Usnic acid and atranorin showed comparable activity against biofilm formation, although atranorin was more active against MRSA. Usnic acid was significantly more active than atranorin against preformed biofilms.. Secondary metabolites of lichens may be considered to be 'lead compounds' for the development of novel molecules for the treatment of S. aureus infections in cystic fibrosis patients.

Topics: Anti-Bacterial Agents; Benzofurans; Biofilms; Biological Products; Colony Count, Microbial; Cystic Fibrosis; Fumarates; Humans; Hydroxybenzoates; Lichens; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Plant Extracts; Staphylococcal Infections